Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Receivables (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Change in Receivables for 9 consecutive years, with $55000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 97.2% to $55000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.6 million through Dec 2025, up 83.11% year-over-year, with the annual reading at -$4.6 million for FY2025, 83.11% up from the prior year.
  • Change in Receivables hit $55000.0 in Q4 2025 for Sutro Biopharma, up from -$4.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $86.0 million in Q2 2022 to a low of -$86.4 million in Q3 2022.
  • Historically, Change in Receivables has averaged -$79550.0 across 5 years, with a median of $125000.0 in 2021.
  • Biggest five-year swings in Change in Receivables: surged 4348.27% in 2022 and later crashed 19425.4% in 2024.
  • Year by year, Change in Receivables stood at $124000.0 in 2021, then tumbled by 3429.03% to -$4.1 million in 2022, then skyrocketed by 571.2% to $19.5 million in 2023, then crashed by 89.92% to $2.0 million in 2024, then crashed by 97.2% to $55000.0 in 2025.
  • Business Quant data shows Change in Receivables for STRO at $55000.0 in Q4 2025, -$4.1 million in Q3 2025, and -$5.6 million in Q2 2025.